What is Corcept Therapeutics Inc worth?
With the base-case assumptions below, a discounted cash flow model on Corcept Therapeutics Inc's reported free cash flow gives $39.86 per share. The share price was $72.61 on November 10, 2026, 82% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $24.54 | -66% |
| Base | 15.0% | 9.0% | $39.86 | -45% |
| Bull | 20.0% | 8.0% | $68.39 | -6% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $51.46 | $55.08 | $59.50 | $65.03 | $72.13 |
| 8.0% | $42.75 | $45.10 | $47.87 | $51.19 | $55.26 |
| 9.0% | $36.41 | $38.01 | $39.86 | $42.02 | $44.57 |
| 10.0% | $31.60 | $32.74 | $34.04 | $35.51 | $37.22 |
| 11.0% | $27.84 | $28.68 | $29.61 | $30.66 | $31.85 |
Where the presets come from
Base: years 1 to 5 grow at Corcept Therapeutics Inc's revenue growth rate over the last 5 fiscal years (16.6% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions